Facial injectables sales will grow through 2036, led by botulinum toxin at 45.0% share in 2026. Facial line correction represents 39.0% share. Market value is estimated at USD 14.94 billion in 2025 and is projected to reach USD 29.94 billion by 2036, adding USD 14.30 billion in value.